Abrocitinib is an oral selective JAK1 inhibitor approved in Europe, the United States and Japan for the treatment of moderate-to-severe atopic dermatitis in adults whose disease is not controlled with other systemic therapies, including biologics, or when the use of such therapies is not indicated. Here, JAK1 is linked to atopic eczema.